News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
NeurAxon, A Canadian Biotech Firm Focused On Pain, Gets $1.2 Million Seed Round
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NeurAxon Inc., a biotech start-up focused on new treatments for pain, has raised C$2.5 million ($1.8 million) in its first round of outside venture funding.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
Earnings
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
July 27, 2026
·
3 min read
·
Tristan Manalac
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
July 27, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
Amgen lays off around 40 employees
July 26, 2026
·
70 min read
·
BioSpace Editorial Staff
Drug Development
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
July 24, 2026
·
3 min read
·
Gabrielle Masson
